Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2013

Open Access 01-12-2013 | Case report

A case report of de novo hepatocellular carcinoma after living donor liver transplantation

Authors: Songfeng Yu, Hua Guo, Li Zhuang, Jun Yu, Sheng Yan, Min Zhang, Weilin Wang, Shusen Zheng

Published in: World Journal of Surgical Oncology | Issue 1/2013

Login to get access

Abstract

Post-transplant malignancy is the major cause of later death of recipients after liver transplantation. Tumor recurrence after liver transplantation for patients with hepatocellular carcinoma in the end stage of cirrhosis has been frequently encountered. However, de novo hepatocellular carcinoma originating from the liver allograft has only rarely been reported. Here we reported a case of de novo hepatocellular carcinoma developed 2 years after living donor liver transplantation for hepatitis B-related liver cirrhosis with viral YMDD mutation. To the best of our knowledge, this is the first report of de novo hepatocellular carcinoma in a liver graft with recurrent hepatitis B virus infection after liver transplantation for hepatitis B-related liver cirrhosis with YMDD mutation. Moreover, the de novo cancer first presented as a lung mass with minimal liver involvement and was obscured by a pulmonary fungal infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Herrero JI: De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009, 15 (Suppl 2): S90-S94.CrossRefPubMed Herrero JI: De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009, 15 (Suppl 2): S90-S94.CrossRefPubMed
2.
go back to reference Yao FY: Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008, 8: 1982-1989. 10.1111/j.1600-6143.2008.02351.x.CrossRefPubMed Yao FY: Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008, 8: 1982-1989. 10.1111/j.1600-6143.2008.02351.x.CrossRefPubMed
3.
go back to reference Torbenson M, Grover D, Boitnott J, Klein A, Molmenti E: De novo hepatocellular carcinoma in a liver allograft associated with recurrent hepatitis B. Transplant Proc. 2005, 37: 2205-2206. 10.1016/j.transproceed.2005.03.093.CrossRefPubMed Torbenson M, Grover D, Boitnott J, Klein A, Molmenti E: De novo hepatocellular carcinoma in a liver allograft associated with recurrent hepatitis B. Transplant Proc. 2005, 37: 2205-2206. 10.1016/j.transproceed.2005.03.093.CrossRefPubMed
4.
go back to reference Saxena R, Ye MQ, Emre S, Klion F, Nalesnik MA, Thung SN: De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Liver Transpl Surg. 1999, 5: 81-82. 10.1002/lt.500050111.CrossRefPubMed Saxena R, Ye MQ, Emre S, Klion F, Nalesnik MA, Thung SN: De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Liver Transpl Surg. 1999, 5: 81-82. 10.1002/lt.500050111.CrossRefPubMed
5.
go back to reference Levitsky J, Faust TW, Cohen SM, Te HS: Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. Liver Transpl. 2002, 8: 572-10.1053/jlts.2002.33275.CrossRefPubMed Levitsky J, Faust TW, Cohen SM, Te HS: Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. Liver Transpl. 2002, 8: 572-10.1053/jlts.2002.33275.CrossRefPubMed
6.
go back to reference Croitoru A, Schiano TD, Schwartz M, Roayaie S, Xu R, Suriawinata A, Fiel MI: De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci. 2006, 51: 1780-1782. 10.1007/s10620-006-9333-8.CrossRefPubMed Croitoru A, Schiano TD, Schwartz M, Roayaie S, Xu R, Suriawinata A, Fiel MI: De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci. 2006, 51: 1780-1782. 10.1007/s10620-006-9333-8.CrossRefPubMed
7.
go back to reference Flemming P, Tillmann HL, Barg-Hock H, Kleeberger W, Manns MP, Klempnauer J, Kreipe HH: Donor origin of de novo hepatocellular carcinoma in hepatic allografts. Transplantation. 2003, 76: 871-873. 10.1097/01.TP.0000082819.85398.59.CrossRefPubMed Flemming P, Tillmann HL, Barg-Hock H, Kleeberger W, Manns MP, Klempnauer J, Kreipe HH: Donor origin of de novo hepatocellular carcinoma in hepatic allografts. Transplantation. 2003, 76: 871-873. 10.1097/01.TP.0000082819.85398.59.CrossRefPubMed
8.
go back to reference Kita Y, Klintmalm G, Kobayashi S, Yanaga K: Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci. 2007, 52: 3392-3393. 10.1007/s10620-006-9574-6.CrossRefPubMed Kita Y, Klintmalm G, Kobayashi S, Yanaga K: Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci. 2007, 52: 3392-3393. 10.1007/s10620-006-9574-6.CrossRefPubMed
9.
go back to reference Sotiropoulos GC, Frilling A, Molmenti EP, Brokalaki EI, Beckebaum S, Omar OS, Broelsch CE, Malagó M: De novo hepatocellular carcinoma in recurrent liver cirrhosis after liver transplantation for benign hepatic disease: is a deceased donor re-transplantation justified?. Transplantation. 2006, 82: 1112-CrossRefPubMed Sotiropoulos GC, Frilling A, Molmenti EP, Brokalaki EI, Beckebaum S, Omar OS, Broelsch CE, Malagó M: De novo hepatocellular carcinoma in recurrent liver cirrhosis after liver transplantation for benign hepatic disease: is a deceased donor re-transplantation justified?. Transplantation. 2006, 82: 1112-CrossRefPubMed
10.
go back to reference Vernadakis S, Poetsch M, Weber F, Treckmann J, Mathe Z, Baba HA, Paul A, Kaiser GM: Donor origin de novo HCC in a noncirrhotic liver allograft 3 years after liver transplantation. Transpl Int. 2010, 23: 341-343. 10.1111/j.1432-2277.2009.00942.x.CrossRefPubMed Vernadakis S, Poetsch M, Weber F, Treckmann J, Mathe Z, Baba HA, Paul A, Kaiser GM: Donor origin de novo HCC in a noncirrhotic liver allograft 3 years after liver transplantation. Transpl Int. 2010, 23: 341-343. 10.1111/j.1432-2277.2009.00942.x.CrossRefPubMed
11.
go back to reference Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, Nagata S, Sugimachi K, Gion T, Shirabe K, Maehara Y: De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl. 2009, 15: 1412-1416. 10.1002/lt.21894.CrossRefPubMed Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, Nagata S, Sugimachi K, Gion T, Shirabe K, Maehara Y: De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl. 2009, 15: 1412-1416. 10.1002/lt.21894.CrossRefPubMed
12.
go back to reference Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M: Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006, 12: 253-258. 10.1002/lt.20701.CrossRefPubMed Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M: Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006, 12: 253-258. 10.1002/lt.20701.CrossRefPubMed
13.
go back to reference Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B: De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001, 7: S109-S118. 10.1053/jlts.2001.28645.CrossRefPubMed Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B: De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001, 7: S109-S118. 10.1053/jlts.2001.28645.CrossRefPubMed
14.
go back to reference Dantal J, Soulillou JP: Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005, 352: 1371-1373. 10.1056/NEJMe058018.CrossRefPubMed Dantal J, Soulillou JP: Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005, 352: 1371-1373. 10.1056/NEJMe058018.CrossRefPubMed
15.
go back to reference Penn I: Posttransplant malignancies. Transplant Proc. 1999, 31: 1260-1262. 10.1016/S0041-1345(98)01987-3.CrossRefPubMed Penn I: Posttransplant malignancies. Transplant Proc. 1999, 31: 1260-1262. 10.1016/S0041-1345(98)01987-3.CrossRefPubMed
16.
go back to reference Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Yoon SY, Park CS, Park YH, Lee HJ, Lee SG: De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transplant Proc. 2012, 44: 802-805. 10.1016/j.transproceed.2012.01.027.CrossRefPubMed Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Yoon SY, Park CS, Park YH, Lee HJ, Lee SG: De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transplant Proc. 2012, 44: 802-805. 10.1016/j.transproceed.2012.01.027.CrossRefPubMed
17.
go back to reference Shimizu T, Hayashi M, Inoue Y, Komeda K, Asakuma M, Hirokawa F, Miyamoto Y, Tanigawa N, Uchiyama K: A case of gastric cancer after living donor liver transplantation. Ann Transplant. 2012, 17: 122-126.PubMed Shimizu T, Hayashi M, Inoue Y, Komeda K, Asakuma M, Hirokawa F, Miyamoto Y, Tanigawa N, Uchiyama K: A case of gastric cancer after living donor liver transplantation. Ann Transplant. 2012, 17: 122-126.PubMed
18.
go back to reference Nissen NN, Martin P: Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol. 2002, 35: S79-S85.CrossRefPubMed Nissen NN, Martin P: Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol. 2002, 35: S79-S85.CrossRefPubMed
19.
go back to reference Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D: Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008, 134: 1890-1899. 10.1053/j.gastro.2008.02.064. quiz 2155CrossRefPubMed Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D: Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008, 134: 1890-1899. 10.1053/j.gastro.2008.02.064. quiz 2155CrossRefPubMed
20.
go back to reference Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006, 26: 162-170. 10.1055/s-2006-939758.CrossRefPubMed Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006, 26: 162-170. 10.1055/s-2006-939758.CrossRefPubMed
21.
go back to reference van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA: Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat. 2005, 12: 364-372. 10.1111/j.1365-2893.2005.00620.x.CrossRefPubMed van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA: Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat. 2005, 12: 364-372. 10.1111/j.1365-2893.2005.00620.x.CrossRefPubMed
22.
go back to reference Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H: Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011, 8: 393-10.1186/1743-422X-8-393.PubMedCentralCrossRefPubMed Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H: Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011, 8: 393-10.1186/1743-422X-8-393.PubMedCentralCrossRefPubMed
23.
go back to reference Mas VR, Maluf DG, Dumur CI, Archer KJ, Yanek K, Jackson-Cook C, Fisher RA: Molecular techniques for identifying HCC origin and biology after orthotopic liver transplantation. Diagn Mol Pathol. 2006, 15: 90-94. 10.1097/00019606-200606000-00005.CrossRefPubMed Mas VR, Maluf DG, Dumur CI, Archer KJ, Yanek K, Jackson-Cook C, Fisher RA: Molecular techniques for identifying HCC origin and biology after orthotopic liver transplantation. Diagn Mol Pathol. 2006, 15: 90-94. 10.1097/00019606-200606000-00005.CrossRefPubMed
24.
go back to reference Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H: Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res. 2010, 40: 145-152. 10.1111/j.1872-034X.2009.00582.x.CrossRefPubMed Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H: Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res. 2010, 40: 145-152. 10.1111/j.1872-034X.2009.00582.x.CrossRefPubMed
Metadata
Title
A case report of de novo hepatocellular carcinoma after living donor liver transplantation
Authors
Songfeng Yu
Hua Guo
Li Zhuang
Jun Yu
Sheng Yan
Min Zhang
Weilin Wang
Shusen Zheng
Publication date
01-12-2013
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2013
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-11-176

Other articles of this Issue 1/2013

World Journal of Surgical Oncology 1/2013 Go to the issue